4-Antibody AG

4-Antibody AG was a biopharmaceutical company founded in 2004, with operations in Basel, Switzerland, and Jena, Germany. The company focused on developing a fully human antibody drug-discovery platform to generate antibody therapeutics, primarily for immuno-oncology. Its business model involved making its technology available to pharmaceutical partners through collaborations and generating its own proprietary pipeline of antibody drugs. Key partnerships included long-term collaborations with Boehringer Ingelheim, which commenced in early 2010, and Human Genome Sciences. These collaborations served to validate 4-Antibody's technology platform and provided milestone payments.

The company's core technology was the proprietary in-vitro Retrocyte Display®, a high-throughput platform for the rapid discovery and optimization of fully-human antibodies. This technology utilized a flow cytometry approach with full-length IgG format human antibody libraries expressed in mammalian B cells, which are naturally suited for optimal antibody display. This process was designed to be a fast and efficient source of high-quality therapeutic antibody drug candidates. One of the company's lead development products was an anti-cytomegalovirus antibody drug.

In January 2014, Agenus Inc., a US-based biotechnology company, announced a definitive agreement to acquire 4-Antibody AG. The deal was valued at an initial $10 million in Agenus common stock, with potential additional payments exceeding $40 million based on achieving certain milestones. The acquisition was completed in February 2014. Agenus's stated intention was to retain 4-Antibody's operations and management team, including CEO Dr. Robert Burns. The acquisition provided Agenus with multiple preclinical immune checkpoint antibody programs, including those targeting GITR and OX40.

Keywords: antibody discovery, biopharmaceutical, immuno-oncology, therapeutic antibodies, Retrocyte Display, drug discovery platform, human antibodies, checkpoint inhibitors, Boehringer Ingelheim collaboration, Agenus acquisition, monoclonal antibodies, preclinical development, cancer immunotherapy, GITR, OX40, flow cytometry, antibody engineering, biologics, pharmaceutical partnerships, drug development